Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2013, Article ID 148725, 12 pages
http://dx.doi.org/10.1155/2013/148725
Research Article

Blocking Type I Interferon Signaling Rescues Lymphocytes from Oxidative Stress, Exhaustion, and Apoptosis in a Streptozotocin-Induced Mouse Model of Type I Diabetes

1Zoology Department, Faculty of Science, Minufiya University, Shebin El-Kom, Egypt
2Histology Department, Faculty of Medicine, Assiut University, Assiut, Egypt
3Department of Urology/Surgery, College of Medicine, King Saud University, Saudi Arabia
4Princess Al-Johara Al-Ibrahim Center for Cancer Research, College of Medicine, King Saud University, P.O. Box 7805, Riyadh 11472, Saudi Arabia
5Zoology Department, Faculty of Science, Assiut University, Assiut 71516, Egypt

Received 10 November 2012; Revised 10 January 2013; Accepted 28 January 2013

Academic Editor: Felipe Dal-Pizzol

Copyright © 2013 Hany M. Ibrahim et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. M. Maahs and M. Rewers, “Mortality and renal disease in type 1 diabetes mellitus—progress made, more to be done,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 10, pp. 3757–3759, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. H. E. Thomas and T. W. H. Kay, “Beta cell destruction in the development of autoimmune diabetes in the non-obese diabetic (NOD) mouse,” Diabetes/Metabolism Research and Reviews, vol. 16, no. 4, pp. 251–261, 2000. View at Publisher · View at Google Scholar
  3. H. Beyan, L. R. Buckley, N. Yousaf, M. Londei, and R. D. G. Leslie, “A role for innate immunity in type 1 diabetes?” Diabetes/Metabolism Research and Reviews, vol. 19, no. 2, pp. 89–100, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. T. J. Lyons, “Oxidized low density lipoproteins: a role in the pathogenesis of atherosclerosis in diabetes?” Diabetic Medicine, vol. 8, no. 5, pp. 411–419, 1991. View at Google Scholar · View at Scopus
  5. J. W. Baynes, “Role of oxidative stress in development of complications in diabetes,” Diabetes, vol. 40, no. 4, pp. 405–412, 1991. View at Google Scholar
  6. S. K. Jain, “Hyperglycemia can cause membrane lipid peroxidation and osmotic fragility in human red blood cells,” Journal of Biological Chemistry, vol. 264, no. 35, pp. 21340–21345, 1989. View at Google Scholar
  7. H. Orhan and G. Sahin, “Erythrocyte glutathione S-transferase activity in diabetes mellitus: the effect of the treatment,” Fabad Journal of Pharmaceutical Sciences, vol. 24, no. 3, pp. 127–131, 1999. View at Google Scholar · View at Scopus
  8. Y. Sato, N. Hotta, and N. Sakamoto, “Lipid peroxide level in plasma of diabetic patients,” Biochemical Medicine, vol. 21, no. 1, pp. 104–107, 1979. View at Google Scholar · View at Scopus
  9. H. Kaji, M. Kurasaki, and K. Ito, “Increased lipoperoxide value and glutathione peroxidase activity in blood plasma of type 2 (non-insulin-dependent) diabetic women,” Klinische Wochenschrift, vol. 63, no. 16, pp. 765–768, 1985. View at Google Scholar · View at Scopus
  10. Z. Wang and H. Gleichmann, “GLUT2 in pancreatic islets: crucial target molecule in diabetes induced with multiple low doses of streptozotocin in mice,” Diabetes, vol. 47, no. 1, pp. 50–56, 1998. View at Google Scholar · View at Scopus
  11. G. Brosky and J. Logothetopoulos, “Streptozotocin diabetes in the mouse and guinea pig,” Diabetes, vol. 18, no. 9, pp. 606–611, 1969. View at Google Scholar · View at Scopus
  12. G. Badr, B. M. Badr, M. H. Mahmoud, M. Mohany, D. M. Rabah, and O. Garraud, “Treatment of diabetic mice with undenatured whey protein accelerates the wound healing process by enhancing the expression of MIP-1α, MIP-2, KC, CX3CL1 and TGF-β in wounded tissue,” BMC Immunology, vol. 13, article 32, 2012. View at Google Scholar
  13. G. Badr, “Supplementation with undenatured whey protein during diabetes mellitus improves the healing and closure of diabetic wounds through the rescue of functional long-lived wound macrophages,” Cellular Physiology and Biochemistry, vol. 29, no. 3-4, pp. 571–582, 2012. View at Google Scholar
  14. N. Liadis, K. Murakami, M. Eweida et al., “Caspase-3-dependent β-cell apoptosis in the initiation of autoimmune diabetes mellitus,” Molecular and Cellular Biology, vol. 25, no. 9, pp. 3620–3629, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Lin, N. Yin, B. Murphy et al., “Immune cell-derived C3 is required for autoimmune diabetes induced by multiple low doses of streptozotocin,” Diabetes, vol. 59, pp. 2247–2252, 2010. View at Google Scholar
  16. S. Pestka, C. D. Krause, and M. R. Walter, “Interferons, interferon-like cytokines, and their receptors,” Immunological Reviews, vol. 202, pp. 8–32, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. J. F. Kerr, A. H. Wyllie, and A. R. Currie, “Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics,” British Journal of Cancer, vol. 26, no. 4, pp. 239–257, 1972. View at Google Scholar · View at Scopus
  18. A. N. Theofilopoulos, R. Baccala, B. Beutler, and D. H. Kono, “Type I interferons (α/β) in immunity and autoimmunity,” Annual Review of Immunology, vol. 23, pp. 307–336, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. X. Huang, J. Yuan, A. Goddard et al., “Interferon expression in the pancreases of patients with type I diabetes,” Diabetes, vol. 44, no. 6, pp. 658–664, 1995. View at Google Scholar · View at Scopus
  20. P. Fabris, A. Floreani, G. Tositti, D. Vergani, F. De Lalla, and C. Betterle, “Review article: type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy,” Alimentary Pharmacology and Therapeutics, vol. 18, no. 6, pp. 549–558, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. T. A. Stewart, B. Hultgren, X. Huang, S. Pitts-Meek, J. Hully, and N. J. MacLachlan, “Induction of type I diabetes by interferon-α in transgenic mice,” Science, vol. 260, no. 5116, pp. 1942–1946, 1993. View at Google Scholar · View at Scopus
  22. T. Nakazawa, J. Satoh, K. Takahashi et al., “Complete suppression of insulitis and diabetes in NOD mice lacking interferon regulatory factor-1,” Journal of Autoimmunity, vol. 17, no. 2, pp. 119–125, 2001. View at Publisher · View at Google Scholar · View at Scopus
  23. R. Otton, J. R. Mendonca, and R. Curi, “Diabetes causes marked changes in lymphocyte metabolism,” Journal of Endocrinology, vol. 174, pp. 55–61, 2002. View at Google Scholar
  24. V. B. Shidham and V. K. Swami, “Evaluation of apoptic leukocytes in peripheral blood smears,” Archives of Pathology and Laboratory Medicine, vol. 124, no. 9, pp. 1291–1294, 2000. View at Google Scholar · View at Scopus
  25. M. Tanaka-Kataoka, T. Kunikata, S. Takayama et al., “Oral use of interferon-α delays the onset of insulin-dependent diabetes mellitus in nonobese diabetes mice,” Journal of Interferon and Cytokine Research, vol. 19, no. 8, pp. 877–879, 1999. View at Publisher · View at Google Scholar · View at Scopus
  26. H. M. Saad Eldien, I. A. El-Elaimy, H. M. Ibrahim, B. M. Badr, and G. Badr, “Increased level of Type I Interferon (IFN) during Type I diabetes (T1D) induces apoptosis in spleen-homing T cells,” African Journal of Pharmacy and Pharmacology, vol. 6, no. 37, pp. 2675–2681, 2012. View at Google Scholar
  27. G. Badr, H. Waly, H. M. Saad Eldien et al., “Blocking type i interferon (IFN) signaling impairs antigen responsiveness of circulating lymphocytes and alters their homing to lymphoid organs: protective role of type i IFN,” Cellular Physiology and Biochemistry, vol. 26, no. 6, pp. 1029–1040, 2010. View at Publisher · View at Google Scholar
  28. G. Badr, H. Saad, H. Waly et al., “Type I interferon (IFN-alpha/beta) rescues B-lymphocytes from apoptosis via PI3Kdelta/Akt, Rho-A, NFkappaB and Bcl-2/Bcl(XL),” Cellular Immunology, vol. 263, no. 31, pp. 31–40, 2010. View at Google Scholar
  29. M. E. Baldeon, T. Chun, and H. R. Gaskins, “Interferon-alpha and interferon-gamma differentially affect pancreatic beta-cell phenotype and function,” American Journal of Physiology, vol. 275, no. 1, pp. 25–32, 1998. View at Google Scholar
  30. C. M. Whitacre and M. K. Cathcart, “Oxygen free radical generation and regulation of proliferative activity of human mononuclear cells responding to different mitogens,” Cellular Immunology, vol. 144, no. 2, pp. 287–295, 1992. View at Publisher · View at Google Scholar · View at Scopus
  31. J. W. Baynes, “Role of oxidative stress in the development of complications in diabetes,” Diabetes, vol. 40, pp. 405–412, 1991. View at Google Scholar
  32. P. Rösen, P. P. Nawroth, G. King, W. Möller, H. J. Tritschler, and L. Packer, “The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a congress series sponsored by UNESCO-MCBN, the American diabetes association and the German diabetes society,” Diabetes/Metabolism Research and Reviews, vol. 17, no. 3, pp. 189–212, 2001. View at Publisher · View at Google Scholar · View at Scopus
  33. R. H. Burdon, “Superoxide and hydrogen peroxide in relation to mammalian cell proliferation,” Free Radical Biology and Medicine, vol. 18, pp. 775–794, 1995. View at Google Scholar
  34. S. G. Rønn, N. Billestrup, and T. Mandrup-Poulsen, “Diabetes and suppressors of cytokine signaling proteins,” Diabetes, vol. 56, no. 2, pp. 541–548, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. A. Wȩdrychowicz, H. Dziatkowiak, K. Sztefko, and A. Wȩdrychowicz, “Interleukin-6 (IL-6) and IGF-IGFBP system in children and adolescents with type 1 diabetes mellitus,” Experimental and Clinical Endocrinology and Diabetes, vol. 112, no. 8, pp. 435–439, 2004. View at Publisher · View at Google Scholar · View at Scopus
  36. J. S. Yudkin, M. Kumari, S. E. Humphries, and V. Mohamed-Ali, “Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?” Atherosclerosis, vol. 148, no. 2, pp. 209–214, 2000. View at Publisher · View at Google Scholar · View at Scopus
  37. Y. Dogan, S. Akarsu, B. Ustundag, E. Yilmaz, and M. K. Gurgoze, “Serum IL-1β, IL-2, and IL-6 in insulin-dependent diabetic children,” Mediators of Inflammation, vol. 2006, Article ID 59206, 6 pages, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. J. L. Taylor and S. E. Grossberg, “The effects of interferon-alpha on the production and action of other cytokines,” Seminars in Oncology, vol. 25, pp. 23–29, 1998. View at Google Scholar
  39. M. Masini, D. Campani, U. Boggi et al., “Hepatitis C virus infection and human pancreatic β-cell dysfunction,” Diabetes Care, vol. 28, no. 4, pp. 940–941, 2005. View at Publisher · View at Google Scholar · View at Scopus
  40. P. Fallahi, C. Ferri, S. M. Ferrari, A. Corrado, D. Sansonno, and A. Antonelli, “Cytokines and HCV-related disorders,” Clinical and Developmental Immunology, vol. 2012, Article ID 468107, 10 pages, 2012. View at Publisher · View at Google Scholar
  41. L. Singh, S. K. Arora, D. K. Bakshi, S. Majumdar, and J. D. Wig, “Potential role of CXCL10 in the induction of cell injury and mitochondrial dysfunction,” International Journal of Experimental Pathology, vol. 91, no. 3, pp. 210–223, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. T. K. Means, E. Latz, F. Hayashi, M. R. Murali, D. T. Golenbock, and A. D. Luster, “Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9,” Journal of Clinical Investigation, vol. 115, no. 2, pp. 407–417, 2005. View at Publisher · View at Google Scholar · View at Scopus
  43. M. Chawla-Sarkar, D. J. Lindner, Y. F. Liu et al., “Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis,” Apoptosis, vol. 8, no. 3, pp. 237–249, 2003. View at Publisher · View at Google Scholar · View at Scopus
  44. C. Nielsen, D. Hansen, S. Husby, B. B. Jacobsen, and S. T. Lillevang, “Association of a putative regulatory polymorphism in the PD-1 gene with susceptibility to type 1 diabetes,” Tissue Antigens, vol. 62, no. 6, pp. 492–497, 2003. View at Publisher · View at Google Scholar · View at Scopus
  45. P. Klenerman and A. Hill, “T cells and viral persistence: lessons from diverse infections,” Nature Immunology, vol. 6, pp. 873–879, 2005. View at Google Scholar
  46. D. A. Chesler, C. Dodard, G. Y. Lee, D. E. Levy, and C. S. Reiss, “Interferon-γ-induced inhibition of neuronal vesicular stomatitis virus infection is STAT1 dependent,” Journal of NeuroVirology, vol. 10, no. 1, pp. 57–63, 2004. View at Publisher · View at Google Scholar · View at Scopus
  47. S. E. Lamhamedi-Cherradi, S. Zheng, B. A. Hilliard et al., “Transcriptional regulation of type I diabetes NF-κB,” Journal of Immunology, vol. 171, no. 9, pp. 4886–4892, 2003. View at Google Scholar · View at Scopus
  48. C. H. Yang, A. Murti, S. R. Pfeffer, J. G. Kim, D. B. Donner, and L. M. Pfeffer, “Interferon alpha /beta promotes cell survival by activating nuclear factor kappa B through phosphatidylinositol 3-kinase and AKT,” Journal of Biological Chemistry, vol. 276, pp. 13756–13761, 2001. View at Google Scholar
  49. C. S. Mitsiades, N. Mitsiades, and M. Koutsilieris, “The AKT pathway: molecular targets for anti-cancer drug development,” Current Cancer Drug Targets, vol. 4, no. 3, pp. 235–256, 2004. View at Publisher · View at Google Scholar · View at Scopus